Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.51 |
| ▸ | TEC | P42680 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.51 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.51 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14489809 | 0.90 | ENPP1 (0.50) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL1527928 | 0.90 | EGFR (0.45) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL14489814 | 0.90 | ERBB2 (0.51) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL14489848 | 0.88 | ACHE (0.57) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL3129523 | 0.88 | EGFR (0.56) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL4087511 | 0.88 | EGFR (0.56) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL14489800 | 0.87 | EGFR (0.58) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL2453138 | 0.85 | PIK3CD (0.54) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL29465791 | 0.85 | PIK3CD (0.54) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL29465790 | 0.85 | PIK3CD (0.54) | EGFRERBB2RIPK2RETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007068552-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | disclosed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | BPHL, CYP11B2, CYP11B1 | EGFR 349/4885ERBB2 83/4885RIPK2 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.